Castle Biosciences Crushes Q2 Revenue, Lifts 2026 Outlook
CSTL sits 92% above its 52-week low of $14.59.
Summary
Castle Biosciences delivered a massive Q2 revenue beat — $103.55M vs. $86.24M consensus — and raised full-year 2026 guidance to $365-375M from $345-355M. The 32% surge in core test volumes for DecisionDx-Melanoma and TissueCypher drove the outperformance, offsetting declines in other tests. Management now expects positive Adjusted EBITDA for Q3, Q4, and the full year, a clear inflection toward profitability. This follows a Q1 that already showed improved net loss and strong volume growth, but the magnitude of the Q2 beat and the guidance hike materially change the near-term trajectory. With the stock closing at $24.46 before the release, the results validate the strong buy consensus and $40 median target.
At the time of this announcement, CSTL was trading at $27.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $812.5M. The 52-week trading range was $14.59 to $44.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.